Interpace Biosciences: Up on positive data on thyroid cancer tests
26/10/2020 13:04
** Diagnostics company's IDXG.O shares up ~5% at $4.28 in
premarket trade
** Announces publication of clinical validation study for
thyroid tests in peer-reviewed journal, Diagnostic Cytopathology
** Study shows combination testing with co's thyroid cancer
tests, ThyGeNEXT and ThyraMIR has high sensitivity and
specificity for identifying the cancer
** Study shows better performance of ThyGeNEXT and ThyraMIR
vs. other molecular tests urn:newsml:reuters.com:*:nGNX7D4ZtC
** Stock has fallen 18% this year
(Reporting by Sanjana Shivdas in Bengaluru)
((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))